Market Access, Pricing and Reimbursement 2016 Europe


Background Info

Market Access, Pricing and Reimbursement 2016 Europe

Market access is a complex and protracted process that pharmaceutical and biotech companies go through in order to ensure their products are made available in as many countries as possible and most importantly that these products are reimbursed and made available to patients who needs them. Due to the development of more and more hi-tech drugs coming to the market, market access has become very important over the last 5-10 years resulting in increasing pressure on healthcare systems and/or governments to cut the costs of their drugs bills. For example, the National Institute of Clinical Excellence (NICE) plays a key role in the UK market – deciding whether or not new treatments are cost effective. In order for companies to have their products reimbursed at the best price possible by the NHS they must work harder, gather more data around the health economic impact and cost effectiveness of their products and present their data to NICE.

Today market access has become far more challenging due to a number of factors: the increase of competing drugs in the same therapeutic area, the need to contain rising costs, dependence of evidence based medicine and health technology assessment to influence payer decision. In addition, Biosimilar drugs have given payers more choice in deciding what products they will cover.

It has been said that the emerging markets are a key driver of the global pharmaceutical industry’s growth and will be for years to come. IMS Health has predicted that by 2017 they’ll account for one-third of industry sales and still be growing at double-digit rates.

The two-day Market Access, Pricing and Reimbursement 2016 Europe will provide a unique platform for the convergence of stakeholders in the industry to interact, discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals and non-profit organizations as well as regional and local manufacturers to discuss and share on the macroeconomic factors, policies, issues and drivers that will steer pharmaceutical industry.

Who Will You Meet

Presidents, Heads/Chiefs, Directors, VPs and Managers of:
· Market Access
· Pricing and Reimbursement
· Patient Outcomes
· Health Economics and Outcomes Research
· Payer Relations/ Evidence
· Data Management/ Analysis
· Regulatory Affairs
· Public/ Government Affairs
· Payers, HTA Officials and Physicians

Gain Latest Insights On

Market Access strategies: How can we maximize our strategies?
· Early Market Access of Health Technologies: The implications.
· Challenges & Opportunities in pharma pricing, reimbursement and market access: Changing market trends and influences
· Emerging Markets: What knowledge, strategies and resources will be needed to maximize pricing and access and hurdles faced.
· Pricing & Reimbursement: for Orphan Drugs and Biosimilar
· Patient Access: How can this continue to improve?
· Data Collection & Management: Using Real World Evidence and Patient Reported Outcomes for pricing and access
· International Collaboration: Where do we agree and differ?
· Looking to the Future: What lies ahead?

Key Speakers

Thomas-TmmeThomas Temme, Head of Market Access & Public Affairs Germany, Austria & Switzerland, Shire
Thomas started his career as a business development manager at a biopharmaceutical start-up company, working on 8-digit in- and out-licensing and M&A projects as well as the company’s IPO. In his role as project manager in a strategy consulting firm, he consulted various large German health insurances and medical technology companies and worked on AMNOG processes with a large number of pharmaceutical companies. In 2014, Thomas joined Shire to head the market access and public affairs work in Germany, Austria and Switzerland. He holds a master’s degree in sociology and an MBA.

Frank-ZhangDr. Frank Zhang, Global Head, Pricing and Market Access, Celgene.
Frank is Global Head, Pricing and Market Access of Immunology & Inflammation, Celgene. Prior to joining Celgene in 2010, Frank held leading global Pricing and Market Access positions at J&J and Wyeth. Frank specializes in strategically creating and enhancing value, demonstrating value proposition, and maximizing pricing and market access potentials of pharmaceutical products and portfolios. Frank has a track record of Building franchise P&MA teams from ground up; Driving corporate executive P&MA decisions; Optimizing P&MA potentials through innovative HEOR strategies; and Building creative, effective and comprehensive P&R toolkit with successful launches.

Adam-KunderDr. Adam Kundzewicz ,Senior Global Payer Strategy Manager, Head of Pricing UK, Boehringer Ingelheim
Adam is a Senior Global Payer Strategy Manager working in oncology pipeline at Boehringer Ingelheim. He is managing global pricing and market access strategies for the oncology portfolio and driving the development of innovative market access approaches and payment schemes. Since September 2015 he is also heading the Boehringer Ingelheim Pricing Team working across the whole Boehringer Ingelheim prescription medicines portfolio.
Prior to joining Boehringer Ingelheim Adam worked as a life sciences strategy consultant for IMS Consulting, Truven Analytics and Simon-Kucher & Partners in Belgium, France, Germany, Poland, Romania and The United States. He also worked as a research assistant at Jules Gonin Eye Hospital in Lausanne, Switzerland and as a Junior Project Leader at AnalyCen in Poland and Sweden.
Adam holds a M.Sc. in Molecular Biology and Biotechnology from University of Warsaw, Poland, and a Ph.D. in Neurosciences from University of Geneva, University of Lausanne and EPFL, Switzerland. He has published several articles in international peer reviewed journals, and lectured at international conferences on developmental neuroscience and retinal degeneration.

Simone-BrethDr. Simone Breitkopf, MD PhD Head HEOR, Governmental and Public Affairs, Alcon
Medical Doctor, trained in Psychiatry and Neurology, PhD in Neuropathology, since 1999 different leading positions in Pharmaceutical Industry, from 2006 to 2011 Head Clinical Research and Pharmacovigilance at BPI, German Pharmaceutical Industry Association. Expert in Outcomes Research, Health Care Research, HTA and Pharmacoeconomy, long experience in Public and Governmental Affairs. Since joining Alcon responsibility for pharmaceuticals and devices, involved in German AMNOG procedures and new regulatory framework for devices. Member in various scientific associations like dggoe, DNebM,

Richard-MarshRichard Marsh, Head of Market Access, Allergan
Richard Marsh is Head of Market Access for the UK and Ireland for Allergan, a position he has held since 2013. Prior to that he has worked in market access and government affairs roles for two other major pharmaceutical companies as well as in consultancy. Richard has over 20 years of experience of working with the NHS and in health policy, having also been for five years the special adviser to the Secretary of State for Health.

Ritva-LehtonenRitva Lehtonen, Patient Access and External Affairs Director, Hospital tender, Sanofi
Ritva is currently leading the access and pricing team in Finland for Sanofi group that is responsible for market access strategy and implementation including health economic, pricing and reimbursement as well as hospital tender strategy and implementation. External affairs and stakeholder management is essential part of the access activity. She has more than 20-year experience in the pharma industry for several functions including business as a business unit director, medical as medical director and regulatory as a regulatory manager. She is also working closely with other European countries especially with Nordic and Baltic countries. She is master in pharmacy by training from Helsinki University and eMBA from Helsinki University of Technology, Business Economics. She had taken several continuing education courses in relation to professional tasks like health economic and pricing.

steve-bradshaqSteve Bradshaw, Managing Director, Valid Insight
Steve Bradshaw has had over 16 years in healthcare both as a clinician and as an expert advisor to the pharma industry. His expertise is in developing value-based market access strategies and solutions, including the implementation and use of real-world studies. In the rare and orphan disease space he has experience with multiple products and conditions ranging from Fabry disease through to retinitis pigmentosa.
Dr Bradshaw writes and speaks regularly on the challenges facing the global healthcare environment; he has presented widely and has over 30 publications. His career features being Editor at Nature Clinical Reviews, an ophthalmic surgeon in the NHS, and various positions to senior executive level in market access and HEOR consulting firms. He is a peer reviewer for several industry and medical journals and currently holds a position on the Pharma IQ Advisory Board.

Pearl-GumbaDr. Pearl Gumbs, Senior HEOR Manager, DAIICHI SANKYO
Dr. Pearl Gumbs acquired her MSc in Health Economics and Policy Administration from Maastricht University and MSc in Health Services Research from Erasmus University, Rotterdam. She later obtained her PhD degree in Pharmaco-Economics and Pharmaco-Epidemiology from the Utrecht University. Pearl has over 13 years of experience in both Academia setting and the pharmaceutical industry. She has had the opportunity to lecture and train students on various Market Access and HEOR disciplines across various European Universities. Her pharmaceutical industry experience encompasses over 8 years focusing on Health Economic topics which has led her to fulfil various roles at a Local, Regional and Global setting. Pear is currently working at Daiichi-Sankyo Europe where she is the Regional Sr Manager, Health Economics and Outcomes Research (HEOR) within the Market Access Department. Pearl Gumbs is currently living in Munich, Germany and enjoys various outdoor activities.

Marcus DahlmanMarcus Dahlman, Nordic Head of Market Access, Teva Nordic
Marcus Dahlman, B.Sc., MBA held various Nordic and European Market Access positions in the Biotech industry for the last 13 years. Prior to that he worked as a management consultant. During the years in biotech Marcus covered a wide range of strategic and operational market access aspects, in R&D assets as well as in-market products. He has lead European market access launches of biological treatments within multiple sclerosis.

Alexander-NatzDr. Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Since 2009, Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs ( in Brussels and works as lawyer in his own law firm in Düsseldorf ( From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.

Anne MarciniakDr. Anne Marciniak, Senior Director, International HEOR, Allergan
Anne is currently Senior Director, European HEOR with Allergan. She has 20-year experience in Market Access and Health Economics in the pharmaceutical industry, including Pfizer, Amgen and recently Daiichi-Sankyo. With her teams, she lead the Market Access strategy of multiple compounds in the European environment focussing on meeting the needs of payers at national, regional and local levels. She has hands-on experience in establishing strategies and leading their cross-functional execution, integrating all elements of product value in particular clinical and safety profile, health economics and price. She believe that through engagement of all partners involved in the delivery of health care including payers the best value will be achieved for patients and citizens ultimately financing care.She is a physician by training with qualification in Health Economics and Epidemiology.

TorosToros Şahin, Head of Market Access and Health Economics, Sanofi
Toros Şahin is Market Access & Health Economics Director at Sanofi Group Turkey, responsible for pricing, reimbursement and health economics activities under the umbrella of Sanofi Group (Sanofi, Zentiva, Genzyme). He has received his undergraduate and graduate ( degrees from Boğaziçi University, on Molecular Biology & Genetics. He has also completed a postgraduate program in Health Economics for Healthcare Professionals at the University of York, UK. He previously worked for Sandoz in business development and pricing & reimbursement fields and is working for Sanofi since 2008. He is married with one daughter, fluent in English and beginner in German and Japanese.

Oliver TimmisOliver Timmis, Head of Projects, ALKAPTONURIA SOCIETY (AKU), UK
Oliver Timmis is the Head of Projects for the AKU Society, an entrepreneurial patient organisation supporting those diagnosed with a rare disease, alkaptonuria (AKU). Oliver leads on funding applications for new projects, allowing for the creation of a National AKU Centre for UK patients, and international phase III clinical trials called DevelopAKUre. He graduated with a BA(hons) in Natural Science (Physiology, Development and Neuroscience) from Cambridge University. Oliver volunteers at Eurordis (Rare Diseases Europe) on their DITA (Drug Information, Transparency and Access) taskforce, sits on the Patient Advisory Council at the RD Connect registries project, and is a member of the Patient-centered Special Interest Group at ISPOR. He also volunteers for Findacure, the Fundamental Diseases Partnership.

Frans-vanDr. Frans van Andel, Access of Health Technologies, Board Director PPi Healthcare Consulting Ltd
Dutch nationality. Board Director of PPi Healthcare Consulting Ltd. Degrees in health economics (Universities of Groningen and Utrecht) and public health (Harvard, USA). PhD in pharmaceutical economics. More than 25 years of experience in market access issues involving pharmaceuticals and medical devices with work experience in the pharmaceutical industry, CRO’s and WHO. In addition, investment and healthcare restructuring projects (especially rehabilitation facilities for handicapped persons) for the public and private sector in Central and Eastern Europe, Africa, Middle East and Asia. Assignments from the health insurance sector, medical technology and pharmaceutical industries as well as institutional agencies such as the European Union, the World Bank and the Netherlands’ Government. Expert in market access issues involving pharmaceuticals and medical devices, project development sourcing, health financing and insurance and public/private mix. Fluent in Dutch, English, German. Conversant in French and Russian.

Carla NivenCarla Niven, Senior Principal, Pricing and Market Access, IMS Health

  • Carla has +15 years of experience in P&MA
  • Her therapeutic areas of expertise include Oncology, Diabetes, Pain and Cardiovascular
  • She was Head of Market Access, Pricing and Reimbursement at Takeda Pharma Europe
  • Prior to joining Cambridge Pharma Consultancy in 2000, Carla was a Medical Representative for Merck Sharp and Dohme in the UK
  • Areas of expertise
  • Global Pricing and Market Access strategy development for pre and post launch brands
  • Expertise in Oncology, Orphan diseases, MS, Pain, Diabetes, CV and Gout
  • Education
  • B.Sc Hons in Biological Sciences with Anatomy Honors from the University of Edinburgh
  • Diploma in Marketing from the Chartered Institute of Marketing

  • Rupert GaleRupert Gale, Respiratory Global Market Access Head, GSK
    Rupert Gale is currently the Global Head of Market Access and Pricing for the Respiratory Franchise at GSK. He has over 18 years experience in the pharmaceutical industry, the majority of which has been in the payer field. During this time Rupert has also worked for Novartis, Bayer, and in consulting. His leadership spans the global, regional and local levels and has worked on projects from early development, through multiple HTA submissions in support of reimbursement, to post launch pricing optimisation. His primary interest is the development and implementation of payer customer centric solutions that make a difference to patients by supporting the uptake of effective medicines. Prior to joining the pharma industry Rupert worked in business-to-business marketing where he specialised in strategic customer alliances.

    Gwilyn ThompsonDr. Gwilym Thompson, Health Economics Lead, Diabetes, Janssen
    Gwilym Thompson is a scientist by background, with 14 years’ experience in pharmaceutical development, 8 years of which within industry working for GSK and latterly Janssen. He has worked at Global, Regional (Europe, Middle East and Africa) and for the UK levels within industry as a health economics and outcomes specialist, supporting and leading Health Technology Assessments (HTA). During this time, Gwilym has worked across many therapy areas, including oncology, haematology, diabetes, immunology and Alzheimer’s disease.
    Gwilym’s current role is as Health Economic Lead within the Janssen UK Health Economics, Market Access & Reimbursement team. This role entails the strategic oversight and direction of HTA submissions, input into the clinical development of early stage compounds, input into UK market access strategy and leading a team of health economists.

    Ulf StaginnusUlf Staginnus, Head Patient Access Oncology, Region Europe, Baxalta
    Ulf Staginnus is a health economist and pharmaceutical executive with 20 years of international experience in the field of market access, pharmacoeconomics, pric¬ing and reimbursement as well as health technology valuations within the biotech¬nology and pharmaceutical industry. Ulf currently heads up the EMEA Patient Access Function of Baxalta Oncology. He has a long track record in successfully developing launch pricing and market access strategies for various innovative drugs across different therapeutic areas such as oncology, cardiology, infectious diseases and orphan drugs within the top fifteen pharmaceutical companies (Amgen, Novartis, BMS, Pfizer, GSK Biologics) and biotech start-ups. Other industry positions he has held have included Head of Market Access Europe for PTC Therapeutics and Endocyte Inc, both in Zug, Switzerland; Head of Pricing and Access, Novartis Oncology Europe in Milan, Italy; and Franchise Head, Oncology International Access, Health Economics and Reimbursement with Amgen International in Zug, Switzerland. In 1996, Ulf graduated with an MA in Economics – with a major focus on health economics – from the University of Bayreuth, Germany. During the course of his career he also founded and ran his own consultancy serving biotech and pharma clients in supporting their product pricing, valuations and market access initiatives. He is a regular speaker on access, pricing and health economics-related matters and the author of

    Day 1

    Day 1 – 9th June 2016

    08:30 Registration

    09:15 Chairperson’s Opening Remarks
    Dr. Pearl Gumbs, Senior HEOR Manager, Daiichi Sankyo, GERMANY


    09.30 Early parallel scientific advice EMA/HTAs for successful market access in Europe.

  • The process

  • Experience and key learnings

  • Impact on clinical development process

  • Impact on national HTA
  • Dr. Simone Breitkopf, Head HEOR, Governmental and Public Affairs, Alcon.

    10:10 Holistic Value Creation and Pricing & Market Access Strategy

  • Market access strategy vs. regulatory strategy

  • Value creation process in LCM

  • Collaboration with HEOR
  • Dr. Frank Zhang, Global Head, Pricing and Market Access, Celgene.

    10.50 Morning Break & Networking

    11:30 Accelerated Access: Delusion or Deliverable?

  • Market access in the UK depends on the actions and decisions of hundreds of different payer organisations and influencers as much as on the decisions of bodies such as NICE or the SMC

  • Now is a particularly challenging time for these bodies as they face mounting demands and budgets that are held back by the straitjacket of austerity

  • Despite initiatives such as the UK Government’s Accelerated Access Review, this environment is becoming more rather than less demanding – how should pharma respond?
  • Richard Marsh, Head of Market Access, Allergan

    12:10 The HTA arms race

  • Are evidence requirements becoming wider or deeper?

  • Value vs. uncertainty

  • How does this align with real world data gathering and early access?
  • Dr. Gwilym Thompson, Health Economics Lead, Janssen Pharmaceuticals.

    12.50 Networking Lunch

    14:00 Outcomes of the first 5 years of AMNOG and its international implications

  • Orphan Drugs under AMNOG

  • International Reference Pricing

  • Price Transparency
  • Dr. Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)


    14.40 Challenges in pharma pricing and market access

  • Challenges in access environment including equitable access

  • What are the needs of our stakeholders, budget holders and influencers?

  • Challenges to a long term sight for access strategy

  • What are the issues in localization of the value stories?

  • Finland have suffered economic regression for some years and we are facing several cost containment challenges and saving plans by the government that is very similar to other European countries and the presentation will reflect this.
  • Ritva Lehtonen, Market Access & External Affairs Director, Hospital Tenders, Sanofi.

    15.20 Tea Break & Networking

    16.00 How to overcome the challenges?

  • Ways in which market access can be made successful

  • Local and global knowledge – Keeping up to date on pricing and market access.

  • Understanding the local payer and decision-maker needs as these relate to pricing, reimbursement and market access.

  • Identify and remove all barriers to prescribing, ensuring a rapid uptake of a new product at an optimum price.
  • Steve Bradshaw, Managing Director, Valid Insight.

    16.40 Panel Discussion – The effect of global trends on payer decision-making and market access

  • Current market trends and influences.

  • The impact of market changes on drug development and marketing needs.

  • What is the current and future market value?

  • What is the pricing and reimbursement structure for orphan drugs in US and Europe?
  • Moderator:
    Dr. Anne Marciniak, Senior Director, International HEOR, Allergan

    Dr. Steve Bradshaw, Managing Director, Valid Insight
    Ritva Lehtonen, Patient Access and External Affairs Director, Sanofi

    17.20 Market Access in Turkey: Risks and opportunities in the post Healthcare Transformation Era

  • Overview of Turkish Market Access & Healthcare Environment

  • Basics of the Turkish Pricing & Reimbursement System

  • Changing dynamics of the reimbursement system: Alternative models

  • Government’s mid-long term vision on pharmaceutical industry
  • Toros Şahin, Head of Market Access and Health Economics, Sanofi Turkey Market Access in Turkey: Risks and opportunities in the post Healthcare Transformation Era

    18.00 Chairperson’s Closing Remarks

    Dr. Pearl Gumbs, Senior HEOR Manager, Daiichi Sankyo, GERMANY

    18.00 - 19:00 Networking Drink Reception

    Day 2

    Day 2 – 10th June 2016

    08.30 Registration

    09.10 Chairperson’s Opening Remarks

    Dr. Anne Marciniak, Senior Director, International HEOR, Allergan


    09.30 The evolving Oncology P&MA landscape

  • Pricing and market access trends for novel oncology products
  • Evolving payer evidence requirements (including impact of Immuno-oncologics)
  • Implications for novel oncology products

    Carla Niven, Senior Principal, IMS Health.

    10.10 Very Early Market Access of Health Technologies: What Are the Implications?

  • Concept of "early market access of health technologies"

  • Significance of "early market access" versus "market access"

  • Methods of "early market access"

  • Case studies

  • Approach of PPi Healthcare Consulting Ltd
  • Dr. Frans van Andel, Market Access of Health Technologies Directo9r HEAP Research BV Board Director, PPi Healthcare Consulting Ltd.

    10.50 Morning Break & Networking

    11.30 Three German dossiers: European Orphan Drug access diversity in the DACH nutshell

  • The effects of European rare diseases policy in the last 15 years

  • Similarities and dissimilarities of today’s access procedures for Orphans

  • Some success factors for orphan drug manufacturers accessing diverse European market

  • Country specific and joint themes and outlooks in Orphan drug politics & regulation
  • Thomas Temme, Head if Market Access & Public Affairs, Shire


    12.10 Observational Data (OD) for Market Access purposes: Mind the Gap

  • The gap between research and market access

  • How to craft your data collection strategy?

  • How to disseminate the OD internally and externally?

  • How to close the gap between research and market access?
  • Dr. Pearl Gumbs, Senior HEOR Manager, Daiichi Sankyo

    12.50 Networking Lunch

    14.00 DevelopAKUre: Case study of a patient-centric clinical trial

  • DevelopAKUre, clinical trials for the rare disease, alkaptonuria

  • The role of the patient group in clinical trials

  • How to maximise patient input into the planning and design of clinical trials

  • How to maximise patient retention and patient recruitment during clinical trials

  • Ensure good dissemination of results to patients
  • Oliver Timmis, CEO, AKU Society


    14.40 Are we ready for the Healthcare Future?

  • Where in the value chain will pharma end up?

  • Why patient-centric may not be the (only) future

  • Will regulations force tech-firms to give up health care?

  • Can HTA handle a future with connected e-health and geonomics?
  • Marcus Dahlman, Nordic Head of Market Access, Teva Nordic

    15.20 Tea Break & Networking

    16:00 Future of pharma pricing, reimbursement and market access: What lies ahead?

  • Is the industry ready and equipped to meet the challenges presented?

  • How can the industry respond positively to rising concerns around cost, clinical data and involvement in the research process?

  • How can stakeholders collaborate in order to progress whilst continuing to provide safe and efficacy products?
  • Moderator:
    Dr. Pearl Gumbs, Senior HEOR Manager, Daiichi Sankyo

    Rupert Gale, Franchise Partner Market Access, Respiratory, GSK
    Dr. Adam Kundzewicz, Senior Global Payer Strategy Manager, Head of Pricing UK, Boehringer Ingelheim
    Dr. Anne Marciniak, Senior Director, International HEOR, Allergan
    Ulf Staginnus, Head Patient Access Oncology, Region Europe, Baxalta

    16.40 Chairperson’s Closing Remarks

    Dr. Anne Marciniak, Senior Director, International HEOR, Allergan


    Associate Sponsors

    ppiPPI Healthcare Consulting
    Adding value to commercialisation strategies through local expertise and insight.

    Mission – Our mission is to deliver value through expertise and local market understanding to ensure successful market entry and optimise global business opportunities for our clients in the pharmaceutical, medical device and biotech sectors. We respect ethical principles, accelerating patients’ access to better treatments while delivering a fair added value to our clients.

    History – In 2002 PPi Healthcare Consulting Ltd was established to provide the healthcare industry with specialised support in developing pricing strategies, as well as supporting funding and market access activities. We have offices in 25 countries and for 13 years have been providing global coverage supporting commercialisation, planning and implementation for drugs, diagnostics,medical devices and healthcare services. Our team includes experts who have been working in healthcare market access for many years, and together we have completed around 400 assignments in a multitude of therapy areas.

    Services – Our market access services cover a broad range of areas which companies encounter in bringing technologies to the
    market. Our main services include:

    A. Pricing and Reimbursement (P&R) Consulting Services:
    • Developing national and international pricing strategy throughout product planning process and post-launch
    • Implementing and facilitating P&R submissions and revisions
    • Direct stakeholder and secondary research to inform positioning and value demonstration strategies
    • Supporting pre-approval usage / Early Access

    B. Market Research Consulting Services:
    • Market landscaping and segmentation
    • Product positioning and messaging
    • Stakeholder identification, mapping and decision analysis
    • Payer panels and Advisory board meetings
    • Qualitative and quantitative research

    C. Health Economic Consulting Services:
    • Develop core and country-tailored value / submission dossiers
    • Economic modelling addressing national and sub-national payer requirements
    • Provide value and clinical evidence-generation needs including supportive studies design
    • Supporting Health Technology Assessment (HTA) submissions
    • Systematic reviews

    D. Other Market Access Consulting Services:
    • e.g. launch sequencing assessment, in-licencing and transaction support, ATC (WHO medicines classification system) guidance


    logo-valid-insightValid Insight™: Strength. Strategy. Solutions.

    Delivering real knowledge, valid perspectives and trusted evidence solutions: Valid Insight is here to help conquer your toughest challenges crossing the life science landscape.

    Our in-house advisory board – and unique network of payers, HTA advisors, clinical key opinion leaders and stakeholders in over 40 markets – gives you direct access to some of the world’s prominent advisors and thought leaders in the life science industry.

    Our experts can help you understand value, clinical and marketplace opportunities for new products and therapies. We can then help you build strategy, evidence and marketplace solutions for each step of your product’s research, development and commercialisation lifecycle, which can be used to drive your decision making and help you overcome your toughest challenges in the real world.

    We’re proud that this proven approach not only enables your commercial success, but also supports the delivery of better
    health outcomes for patients and society.


    Media Partners

    Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. For further information please



    PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE’s more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. For further information please visit:



    Bringing the world together through live experiences . We’re creating the world’s first marketplace for live experiences by developing the technology that lets anyone create, share and find new things to do. For further information please



    Select Science is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. is a unique video news channel for laboratory application and product information. For further information please visit:

    pharmiweb is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email:,


    BioProcess International

    BioProcess International™ is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process.


    Global Events List

    Global Events List is an online directory of scientific and medical events from around the world, brought to you by Elsevier. Attending these types of events facilitates the proliferation of scientific discoveries and the building of productive relationships. We hope to play our part by providing the most comprehensive, user-friendly, reliable, and high quality listing of events available.


    Manufacturing Chemist Pharma

    Manufacturing Chemist is among the longest established and most respected information sources in the global pharmaceutical manufacturing industry. Manufacturing Chemist reports on current and future trends in the global marketplace, including the latest developments in drug discovery, biotechnology, drug delivery, ingredients, processing technologies and equipment, packaging, business strategies and regulatory updates. – See more at:



    FiercePharma is the pharma industry’s daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved


    Pharma Phorum is the premier digital publication for thought leadership relating to the pharmaceutical industry. The news, opinions and insights published every day help industry executives better understand the broader healthcare landscape within which they operate, including regular contributions from their peers, innovative service providers, physicians, payers / policy makers, patient organisations and patients.


    Pharmafile is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, and pharma service company listings. Site content is produced by our editorial team for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant


    My Event Guru

    My Event Guru is an interactive portal that allows individuals and businesses to set up, market and promote events, sell tickets and collect RSVP’s, instantly process payments for events online, obtain feedback via sophisticated surveys and generate additional revenue by selling event content.
    Our mission is to be your comprehensive local business event resource. We strive to be the one-stop solution for anyone looking to promote their events, take advantage of our event tools, and generate additional revenue from event content. We are committed to helping you make and maintain local connections and relationships that will make a difference your business and your career.



    Bio-equip is a professional website which provides the information of equipments, consumables, chemical reagents and experimental animals in life science. Our website which takes full advantage of the most up-to-date computer technologies and networks offers the most all-round and considerate service in the information of biology equipments for not only institutes, universities, labs in hospitals but also scientists in bio-engineering and bio-medicine industries and suppliers of lab equipments who would be exposed to comprehensive and well-timed market information to compare the different products in function and price and promote the development of scientific research and industry.

    pharma-tech is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field. Our international scope allows us to examine all pharmaceutical markets closely, from biotechnology to therapeutics, vaccines and



    Conference Alerts is an online conference calendar for academics and professionals. Organizers post conference information on and subscribers receive alerts about conferences in their areas of interest via



    Conferize is the world’s biggest social platform for events. You’re invited.We connect the world of events with speakers, people and media from any industry. We help event organizers build communities, websites and mobile experiences to increase the quality and attendance of their events.


    Originally, was created solely as a directory of conferences, but due to popular demand we are now offering other services. Currently these include:
    • Featured Listings
    • Advertising Opportunities
    • Online Registration Services
    In the future we plan to offer even more services. If you have any requests or suggestions,
    we would love to hear from you. Just drop us an email


    Millennium Gloucester Hotel & Conference Centre, London, United Kingdom

    A 3-minute walk from Gloucester Road tube station, this upscale hotel is 2.4 miles from Buckingham Palace and 1.5 miles from Hyde Park.
    The stylish rooms have flat-screen TVs, minibars and tea and coffeemaking equipment. WiFi is offered for a surcharge. Suites add separate living areas, while club rooms and suites come with private-lounge access, breakfast, beverage/snack vouchers and free WiFi. Room service is available 24/7.
    Amenities include a casual bar serving light bites, a breakfast cafe, an Asian restaurant and an elegant brasserie serving Indian cuisine. There’s also a gym, a business centre and an on-site conference facility.

    Address: 4-18 Harrington Gardens, London, GB SW7 4LH
    Phone: 020 7373 6030